

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Vor Biopharma
Deal Size : $4,125.0 million
Deal Type : Licensing Agreement
Vor Bio Enters into Exclusive Global License Agreement with RemeGen
Details : Vor Bio receives ex-Greater China rights to develop and commercialize RC18 (telitacicept), a novel, dual-target recombinant fusion protein in global Phase 3 for generalized myasthenia gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $45.0 million
June 25, 2025
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Vor Biopharma
Deal Size : $4,125.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : RA Capital Management
Deal Size : $175.0 million
Deal Type : Private Placement
Vor Bio Announces $175 Million Private Placement
Details : The proceeds will be used to fund the clinical development of Vor Bio pipeline, which includes RC18 (telitacicept), a novel, dual-target recombinant fusion protein.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
June 25, 2025
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : RA Capital Management
Deal Size : $175.0 million
Deal Type : Private Placement

Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telitacicept for the Treatment of Refractory RA
Details : Telitacicept is a Protein drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 06, 2025
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
Details : Telitacicept is a BLyS/APRIL inhbitor, which has been approved by NMPA for the treatment of adults with anti-AChR antibody-positive gMG in combination with conventional therapies.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 27, 2025
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RemeGen Files Marketing Application for Telitaccept in Myasthenia Gravis in China
Details : RC18 (telitacicept) targets BLyS and a proliferation inducing ligand, which allows it to effectively reduce B-cell mediated autoimmune responses diseases like generalized myasthenia gravis.
Product Name : Taicercept
Product Type : Protein
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telitacicept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 12, 2024
Lead Product(s) : Telitacicept
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telitacicept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 13, 2024
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
Details : Telitacicept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 13, 2024
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RemeGen Completes Enrollment in Phase III Trials of Telitacicept for IgA Nephropathy
Details : RC18 (telitacicept) targets BLyS and a proliferation inducing ligand, which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in autoimmune diseases like IgAN.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RemeGen's Telitacicept Granted Fast Track Designation for Primary Sjögren's Syndrome
Details : RC18 (telitacicept) targets BLyS and APRIL, two critical molecules for B-cell development, effectively reducing autoimmune responses in several autoimmune diseases by modulating B-cell activity.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 02, 2024
Lead Product(s) : Telitacicept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
